Marisa Wexler, MS, senior science writer —

After years of delays, medical device company Photopharmics has started a pivotal clinical trial to test its Celeste device, a noninvasive treatment tool that aims to use light to manage the symptoms of Parkinson’s disease. The long-awaited trial has been in the works since 2020, shortly after…

Irlab Therapeutics is preparing to start a Phase 3 clinical trial of mesdopetam, its experimental oral treatment intending to ease levodopa-induced dyskinesia, the uncontrolled movements affecting people with Parkinson’s disease. After announcing results of a Phase 2 trial of mesdopetam, Irlab requested an end-of-Phase 2…

A new system that uses artificial intelligence (AI) to analyze videos of people walking may help speed the diagnosis of Parkinson’s disease. Scientists at China Medical University Hospital (CMUH) in Taiwan developed the technology, which can help physicians diagnose Parkinson’s more efficiently and get patients faster access to treatment,…

Playing rehabilitative video games along with physical therapy is more effective than conventional physical therapy only for managing symptoms of Parkinson’s disease, a study suggests. Video game-based therapy is also a better add-on to traditional physical therapy than motor imagery where a patient visualizes the steps needed for complex…

Ventyx Biosciences plans to launch a Phase 2a clinical trial testing VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein, in people with early Parkinson’s disease in the second half of this year. Top-line results from a Phase 1 study in healthy…

Treatment with UB-312, a vaccine designed to trigger an immune response against toxic clumps of the alpha-synuclein protein, reduced these damaging aggregations in people with Parkinson’s disease in a Phase 1 trial. The findings, announced by UB-312’s developer Vaxxinity and presented at the at the AD/PD 2024…

By activating an enzyme known as beta-glucocerebrosidase, or GCase, the experimental therapy GT-02287 is able to improve nerve survival and reduce the dysfunction of lysosomes — structures that work like cellular garbage disposal systems and clear away molecular debris — in cell models of Parkinson’s disease. The Gain…

Dosing has begun in the second part of a Phase 1 clinical trial of GT-02287, an experimental oral therapy that Gain Therapeutics is developing as a treatment for Parkinson’s disease associated with mutations in the GBA1 gene. “Our Phase 1 clinical trial of GT-02287 remains on track…

Participating in high-intensity exercise can help protect the brain from progressive damage in Parkinson’s disease, a proof-of-concept imaging study suggests. “This is the first time imaging has been used to confirm that the biology of the brain in those suffering with Parkinson’s disease is changed by intense exercise,” Evan…

By mapping neurological circuits in the brain, an international team of researchers created a model of brain dysfunction that could help to better guide a surgical treatment for Parkinson’s disease and other brain disorders. Findings were published in Nature Nuroscience, in the study “Mapping dysfunctional circuits…